Key result
Joint AHA and ACCF statement reviews the cardiovascular risks of thiazolidinedione drugs.
Key points are not available for this paper at this time.
Design
Other
Alerts clinicians to thiazolidinedione CV risks; leaves open need for updated outcome trials with contemporary agents.
The American Heart Association and the American College of Cardiology Foundation make every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a
No takes yet. Share an insight, caveat, or question.
Kaul et al. (2010) studied this question. Thiazolidinedione drugs and their associated cardiovascular risks were reviewed in a joint statement by the American Heart Association and the American College of Cardiology Foundation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: